

Special Issue

Molecular Insights into Drug Development for Alzheimer's Disease

Message from the Guest Editors

Current drug treatments for Alzheimer's disease are very limited, with only four inhibitors of neurotransmitters on the market to relieve the symptoms of the condition. With the failure of a number of monoclonal antibodies targeting A β over the past decades, the first monoclonal antibody, Lecanemab (Aduhelm®), was approved by the FDA in 2022, albeit it is continuing to undergo phase III clinical trials. Therefore, the discovery and development of novel disease-modifying drugs for the treatment of Alzheimer's disease is a hugely unmet clinical need. We warmly welcome contributions on the latest developments in the following topics: novel drug target and validation, the discovery and development of novel drug candidates, including small molecules and biologics, drug repurposing, gene therapy, advanced drug delivery systems, and pre-clinical models for drug evaluation. The Special Issue calls for original research, reviews, and short communications that address the progress and identify any knowledge gap at a molecular level in the drug development of Alzheimer's disease.

Guest Editors

Dr. Zheyang Zhu

School of Pharmacy, the University of Nottingham, University Park, Nottingham NG7 2RD, UK

Prof. Dr. Qiulun Lu

State Key Laboratory of Natural Medicines, Jiangsu Province Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China

Deadline for manuscript submissions

closed (31 December 2023)



International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/164640

*International Journal of
Molecular Sciences*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ijms@mdpi.com

[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)





International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)



About the Journal

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Editor-in-Chief

Prof. Dr. José L. Quiles
Department of Physiology, Institute of Nutrition and Food Technology
"Jose Mataix", Biomedical Research Center, University of Granada,
Avda. Conocimiento s/n, 18100 Armilla, Granada, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)